UR 1505

Drug Profile

UR 1505

Alternative Names: UR-1505

Latest Information Update: 27 Aug 2015

Price : $50

At a glance

  • Originator Uriach
  • Developer Palau Pharma
  • Class Antipsoriatics; Salicylates
  • Mechanism of Action Lymphocyte inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Discontinued Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 01 Jul 2015 Palau Pharma completes a phase II trial in Atopic dermatitis in France (EudraCT2007-002550-27)
  • 24 Jul 2007 Discontinued - Preclinical for Transplant rejection in Spain (unspecified route)
  • 24 Jul 2007 Discontinued - Preclinical for Rheumatoid arthritis in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top